Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020


 

Management of ET and PV in 2020: Ruxolitinib in Pts with HU-Resistant/Intolerant Pts, Hydroxyurea & Ropeginterferon Alfa-2b in PV

29 views
March 4, 2020
0 Comments
Login to view comments. Click here to Login
Malignant Hematology